#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15916	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2146	738.5	0	.	n	.	0	C451T	SNP	451	451	C	759	759	T	923	T,C	862,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15916	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2146	738.5	0	.	n	.	0	C1450T	SNP	1450	1450	C	1758	1758	T	907	T,C	827,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15916	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2146	738.5	1	SNP	n	C1184T	0	.	.	1184	1184	C	1492	1492	C	870	C,T	801,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28492	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3540	802.6	0	.	n	.	0	T695C	SNP	695	695	T	1040	1040	C	847	C	801	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28492	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3540	802.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2316	2316	C	901	C,T,A	836,3,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28492	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3540	802.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2390	2390	A	917	A	857	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28492	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3540	802.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2942	2942	C	936	C,T	881,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	2332	folP	852	852	100.0	folP.l15.c30.ctg.1	1535	151.1	1	SNP	p	R228S	0	.	.	682	684	CGC	1021	1023	CGC	226;229;229	C;G;C	213;215;215	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5728	gyrA	2751	2751	99.78	gyrA.l15.c17.ctg.1	3195	178.4	0	.	p	.	0	V19I	NONSYN	55	57	GTC	253	255	ATC	158;161;160	A;T;C	147;151;150	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5728	gyrA	2751	2751	99.78	gyrA.l15.c17.ctg.1	3195	178.4	0	.	p	.	0	M250I	NONSYN	748	750	ATG	946	948	ATA	206;207;206	A;T;A	194;195;195	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5728	gyrA	2751	2751	99.78	gyrA.l15.c17.ctg.1	3195	178.4	1	SNP	p	S91F	0	.	.	271	273	TCC	469	471	TCC	217;217;218	T;C;C	202;206;205	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5728	gyrA	2751	2751	99.78	gyrA.l15.c17.ctg.1	3195	178.4	1	SNP	p	D95N	0	.	.	283	285	GAC	481	483	GAC	215;214;213	G;A;C	196;193;194	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5728	gyrA	2751	2751	99.78	gyrA.l15.c17.ctg.1	3195	178.4	1	SNP	p	D95G	0	.	.	283	285	GAC	481	483	GAC	215;214;213	G;A;C	196;193;194	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1778	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1291	137.1	0	.	p	.	0	D79N	NONSYN	235	237	GAT	603	605	AAT	220;220;221	A;A;T	202;202;202	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1778	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1291	137.1	0	.	p	.	0	M198fs	FSHIFT	592	592	A	960	960	A	216	A	202	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	531	1778	mtrR	633	633	99.68	mtrR.l15.c4.ctg.1	1291	137.1	1	SNP	p	G45D	0	.	.	133	135	GGC	501	503	GGC	239;238;237	G;G;C	225;224;223	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	952	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	916	103.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1634	1636	GCC	210;213;217	G;C;C	197;200;205	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1676	1678	GCA	207;203;204	G;C,T;A,G	195;187,1;178,1	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	1	SNP	p	D86N	0	.	.	256	258	GAC	629	631	GAC	209;208;211	G;A;C	196;186;196	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	1	SNP	p	S87W	0	.	.	259	261	AGT	632	634	AGT	214;212;211	A;G;T	194;197;193	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	1	SNP	p	S87I	0	.	.	259	261	AGT	632	634	AGT	214;212;211	A;G;T	194;197;193	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	1	SNP	p	S87R	0	.	.	259	261	AGT	632	634	AGT	214;212;211	A;G;T	194;197;193	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5218	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2970	175.1	1	SNP	p	S88P	0	.	.	262	264	TCC	635	637	TCC	212;212;210	T;C;C,T	193;198;194,1	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	5086	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2568	197.1	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1549	1551	GGC	244;241;238	G;G;C	227;224;220	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1297	1299	GCA	230;228;226	G;C;A	208;206;211	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1300	1302	ATC	224;223;224	A;T;C	207;204;204	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1312	1314	GTG	216;215;219	G;T;G	202;196;196	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1312	1314	GTG	216;215;219	G;T;G	202;196;196	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1813	1815	ACC	231;230;233	A;C;C	214;216;221	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1867	1869	GCG	247;242;243	G;C;G	200;191;193	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1867	1869	GCG	247;242;243	G;C;G	200;191;193	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	G542S	0	.	.	1624	1626	GGC	1990	1992	GGC	183;182;182	G;G;C	166;166;165	penA.0.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	G545S	0	.	.	1633	1635	GGC	1999	2001	GGC	172;166;164	G;G;C	155;150;153	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	4510	penA	1746	1746	100.0	penA.l15.c30.ctg.1	2410	186.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2017	2019	CCG	140;142;143	C,G;C,G;G	107,4;106,1;109	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6484	ponA	2397	2397	99.87	ponA.l15.c30.ctg.1	3185	203.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2420	porA	1146	1146	99.74	porA.l6.c30.ctg.2	1452	163.1	0	.	p	.	0	S22G	NONSYN	64	66	AGC	164	166	GGC	185;185;184	G;G;C	166;167;164	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2420	porA	1146	1146	99.74	porA.l6.c30.ctg.2	1452	163.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	346	346	C	190	C	175	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	738	740	CAA	224;226;229	C;A;A	204;209;212	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	E212D	NONSYN	634	636	GAA	945	947	GAT	223;222;222	G;A;T	205;203;204	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	H213G	NONSYN	637	639	CAT	948	950	GGT	224;223;223	G;G,T;T	205;205,1;207	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	I218M	NONSYN	652	654	ATC	963	965	ATG	229;227;223	A;T;G	215;215;211	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	R257T	NONSYN	769	771	AGG	1080	1082	ACG	256;258;256	A;C,A;G	241;242,1;242	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1086	1088	GTT	240;238;240	G;T;T	227;225;229	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1200	1202	AAC	265;261;259	A,G;A;C	243,1;246;240	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3030	porB1b	1047	1047	98.95	porB1b.l15.c17.ctg.1	1502	201.2	1	SNP	p	G120K	0	.	.	358	360	GGC	669	671	GGC	234;230;228	G,A;G,A;C,G	214,1;209,1;206,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	11450	rpoB	4179	4179	99.93	rpoB.l15.c30.ctg.1	4800	237.8	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1902	1904	CAT	267;269;268	C;A;T	252;256;254	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1176	rpsJ	312	312	100.0	rpsJ.l6.c4.ctg.1	934	124.7	1	SNP	p	V57M	0	.	.	169	171	GTG	420	422	GTG	246;248;251	G,A;T;G	224,1;226;226	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
